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Over the past decade, there has been an increase in new anti-asthma 
medications, particularly in biological agents recommended for 
adult asthmatics.[1] Despite the increased access to novel agents, 
there has been a dearth of data and recommendations on the 
positioning of these drugs in the paediatric arena. Although 
children with severe asthma are  a smaller component of the total 
asthmatic population (˂5%), there is a need for evidence-based 
recommendations for the use of these novel drugs in asthmatic 
children, as they consume a disproportionate amount of healthcare 
resources.[2,3] Biological agents are typically recommended for use in 
specific asthma phenotypes and endotypes, with predefined criteria 
predicting treatment response.[4,5] 
The role of asthma comorbidities and asthma education has been 
emphasised in the most recent international guidelines, with patient 
adherence and motivation forming a critical part of a package of care 
for asthma management and successful therapy.[1] 
The purpose of this continuing medical education article is to 
review the current literature on novel asthma drugs and to assess the 
evidence for their use or avoidance in the paediatric age group. The 
role of asthma education and strategies to improve asthma outcomes 
are also reviewed.
Methods
The South African Childhood Asthma Working Group (SACAWG) 
convened in January 2017 to review the current available literature 
on novel treatments of asthma and asthma self-management plans 
(Appendix A). The scientific literature was assigned evidence levels 
according to the Grades of Recommendation Assessment, Development 
and Evaluation (GRADE) system (Appendix B).
Novel asthma molecules in South Africa
Fluticasone furoate/vilanterol
Few studies have been done in children with the new combination agent 
of an inhaled corticosteroid (ICS) and an ultra-long-acting beta-agonist. In 
5 - 11-year-old patients with well-controlled asthma, fluti ca sone furoate/
vilanterol has a similar tolerability, safety profile, pharmacodynamic effect 
and pharmacokinetic profile as fluticasone furoate alone.[6,7] The new com-
bination drug is currently registered for children >12 years of age and rec-
ommended for children with moderate to severe asthma (evidence level B)
Tiotropium bromide 
Tiotropium bromide is a once-daily long-acting anticholinergic 
drug initially approved for chronic obstructive pulmonary disease 
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(COPD). In trials involving children, tiotropium improved lung 
function as an add-on treatment to ICSs. It may contribute towards 
preventing asthma exacerbations (evidence level B).[8] It has a role only 
in those with severe asthma who do not respond to either medium-
dose ICSs and long-acting beta-agonists (LABAs) or a combination 
low-dose ICS, LABA and leukotriene receptor antagonist (step 4). 
This drug is only recommended in child ren ≥12 years old.
Novel asthma therapies currently not 
recommended in South Africa
Allergen immunotherapy 
The position of subcutaneous immunotherapy (SCIT) and sublingual 
immunotherapy (SLIT) as potential therapeutic options for asthma has 
yet to be clearly established in international asthma guidelines.[9,10] A 
meta-analysis of 98 studies found that SCIT significantly reduced asthma 
symptoms and medication use and improved bronchial hyperactivity, but 
demonstrated no effect on lung function, asthma control or exacerbation.[11] 
SLIT has been proposed as a more feasible option compared with 
SCIT. A meta-analysis of 52 studies on SLIT in asthma revealed that 
there were limited data to draw any conclusions, given the lack of 
reporting of important outcomes, such as exacerbations and quality 
of life (evidence level III).[12] Furthermore, the majority were mild or 
intermittent asthmatics, limiting the applicability of the results for 
severe asthmatics. Currently, in South Africa (SA), immunotherapy 
remains a relatively inaccessible and expensive treatment option for 
asthma and should not be considered as routine therapy.
Monoclonal anti-IgE 
Omalizumab (OM) is a recombinant DNA-derived humanised 
monoclonal antibody licensed for use in children >6 years of age. It 
binds to the Fc portion of the IgE molecule and decreases unbound 
IgE. There is good-quality evidence from large meta-analyses in 
moderate to severe asthmatics that shows a decreased exacerbation 
rate, decreased duration of hospitalisation and increased withdrawal 
of ICSs.[13,14] In children 6 - 11 years of age with severe allergic 
asthma, OM reduced clinically significant exacerbations but not 
severe exacerbations.[15] During a 1-year study, OM was found to be 
safe, it increased quality of life and global evaluation of treatment 
effectiveness, and allowed complete withdrawal of steroids with no 
increase in adverse drug reactions (evidence level A).[16,17] Evidence 
for the use of OM in children with severe persistent asthma is lacking, 
as most studies were conducted in moderate asthmatics. Predicting 
and evaluating response to OM in cases of severe asthma remain 
uncertain, as OM is equally beneficial in patients with low or high IgE 
levels and data in severe asthma are limited and based on anectodal 
evidence (evidence level D). Currently, use of this agent should 
only be on subspecialist recommendation, when all other causes of 
uncontrolled asthma have been investigated and ruled out and costs 
have been taken into consideration.
Other biological agents
Mepolizumab (anti-interleukin-5 (anti-IL-5)), reslizumab (anti-IL-5), 
lebrikizumab (IL-13) and dupilumab (anti-IL-4 receptor shared by 
IL-4 and IL-13) are newer monoclonal antibodies. Many trials with 
these drugs have been conducted in adult asthmatics, but there are 
not yet any published trials on paediatric asthma. These agents may 
be useful for severe uncontrolled asthma, but cannot currently be 
recommended owing to a lack of data and because of the cost.
Bronchial thermoplasty
There are no data on bronchial thermoplasty in children.
Macrolides 
Macrolide antibiotics have antimicrobial and anti-inflammatory 
properties, which may benefit asthma control. The available evidence 
on macrolide antibiotic use in chronic asthma, and especially chronic 
paediatric asthma, is of low quality. Some patients with uncontrolled 
asthma have chronic Chlamydia pneumoniae, Mycoplasma pneumo-
niae or protracted bacterial bronchitis, which may contribute to 
lack of symptom control. Macrolide antibiotics may assist in the 
eradication of these infections and contribute towards the resolution 
of asthma symptoms.[18]
A recent systematic review and meta -analysis assessed the effects 
of macrolide antibiotics in chronic asthma. Macrolide treatment 
was not better than placebo for most clinical outcomes, including 
exacerbations requiring hospital admission (evidence level C).[19] 
We should not lose sight of the risk for development of macrolide-
resistant bacteria.[20,21] Current evidence therefore does not support 
the routine use of macrolides. 
Antihistamines 
Antihistamines have no benefit for asthma symptom control, but may 
be useful for control of symptoms of co-existing allergic diseases, 
such as rhinitis, conjunctivitis and atopic eczema, where topical 
therapy alone is insufficient to control symptoms.
Vitamin D 
Several cross-sectional studies have shown that low serum levels of 
vitamin D are linked to impaired lung function, higher exacerbation 
frequency and reduced corticosteroid response. However, to date, 
vitamin D supplementation has not been associated with improve-
ment in asthma control or reduction in exacerbations, although the 
quality of studies included in meta-analyses was low to very low 
(evidence level C).[22]
Other drugs and therapies 
The following are of no benefit in the treatment of childhood 
asthma: antibiotics, cough syrups, mucolytics, ionisers and 
breathing exercises. Complementary and alternative medications 
and interventions bear insufficient evidence to permit recommen-
dations. Physiotherapy is indicated in children only where lobar 
collapse is documented.
Immunisation
Influenza contributes to some acute asthma exacerbations, and 
patients with moderate to severe asthma should receive an influenza 
vaccination every year (evidence level D).[1] However, vaccination 
does not reduce the frequency or severity of asthma exacerbations 
(evidence level A). There is no evidence for an increase in asthma 
exacerbations after vaccination with inactivated trivalent vaccines 
compared with placebo. People with asthma, particularly children 
and the elderly, are at higher risk of pneumococcal disease, but 
there is insufficient evidence to recommend routine pneumococcal 
vaccination in people with asthma (evidence level D).[1]
Key strategies to manage poorly controlled asthmatics
Reduction of exposure to avoidable triggers is encouraged, 
particularly where there is a clear association between exposure 
and symptoms. Environmental tobacco smoke (ETS) exposure is 
an important avoidable trigger of asthma exacerbations. There is 
significant evidence of chronic ETS exposure associated with asthma 
exacerbations in preschool children and suggestive evidence of 
this in older children (evidence level D).[23,24] Indoor air pollution 
621       August 2018, Vol. 108, No. 8
CME
from the use of alternative fuel sources may be associated with 
asthma exacerbations. There is sufficient evidence that certain 
chemicals, such as nitrogen dioxide, increase airway responsiveness, 
but evidence is less clear with other chemicals.[25] It is also vital to rule 
out potential comorbidities that could exacerbate asthma symptoms 
and result in poor asthma control (Table 1).
Self-management plans and education
Adherence
Adequate adherence to a treatment plan is key for optimal therapeutic 
benefit. Adherence comprises distinct phases of treatment initiation, 
implementation (including the correct dosing, frequency and technique 
of administration) and persistence. A patient-centred approach that 
delivers holistic, empowering care that is tailored to the individual’s 
priorities and needs is necessary to support adherence (Table 2).
The responsibility for patient education and support rests with 
the doctor, and should be shared with other trained healthcare 
professionals. Patients and parents must be encouraged to participate 
actively in their own management. The objective of this partnership 
is to enable asthma patients to gain the knowledge, confidence and 
skills to assume a major role in the management of their asthma. 
The partnership is formed and strengthened as patients and their 
healthcare professionals discuss and agree on the goals of treatment, 
and develop a personalised, written self-management action plan, 
including self-monitoring, and periodically review the patient’s 
treatment and level of asthma control. The ability or willingness of 
patients to take responsibility varies and thus the information and 
skills training required by each patient differ. All patients require 
certain core information and skills, but most education must be 
personalised.
Educational programmes should be considered a part of routine 
care of all asthma patients. Asthma self-management education 
should be integrated into all aspects of asthma care and reinforced at 
each follow-up visit. Educational programmes significantly improve 
asthma control, quality of life and lung function testing, and decrease 
hospitalisation rates (evidence level A). The influence of education 
is greater in moderate-to-severe than mild-to-moderate asthma 
(evidence level A). Intensive education is of greater benefit than 
limited education, and written plans are superior to oral instructions 
(evidence level A). Education given at follow-up visits is more 
effective than education during emergency visits (evidence level A). 
Culture-specific programmes for asthmatic adults and children are 
more effective than generic programmes in improving quality of life, 
asthma knowledge, exacerbations and control (evidence level B). The 
current evidence base is not sufficient to assess the use of digital self-
management, such as smartphone and tablet computer applications 
for the delivery of asthma self-management programmes.
Strategies for effective education stress that the approach to the 
patient with an ‘attentive listening technique’ affects success of the 
intervention (evidence level C). A ‘tell-back’ approach, whereby 
Table 1. Comorbidities that may result in poor asthma control
Disease Diagnosis Treatment
Rhinoconjuctivitis/sinusitis Symptoms of itchy, runny or blocked nose
Allergic shiners, recurrent otitis media, pale enlarged 
turbinates and conjuntivitis
Allergen avoidance, education, intranasal 
steroids, antihistamines, eye drops and 
immunotherapy
Obesity Prevalence increasing in South African children 
Weight-for-age or BMI >2 standard deviations 
Lifestyle modification, exercise and 
psychosocial management
GORD GORD occurs in 80% of asthmatic children
No gold standard diagnostic test
Proton pump inhibitors
Allergic bronchopulmonary aspergillosis 25% of poorly controlled asthmatics
Total IgE elevated, positive immediate skin test and 
elevated serum IgE and/or IgG for Aspergillus and 
central bronchiectasis
Systemic steroids (evidence level C) and 
antifungals
BMI = body mass index; GORD = gastro-oesophageal reflux disease.
Table 2. Methods to improve adherence
Behavioural factors[26] Educational factors[27,28] Other tools[29] 
Evidence level B Evidence level B Evidence level C
 Help parents to develop a behavioural chart 
or reward system 
 Help patients to link the administration of 
medication with established daily activities  
(e.g. meal time, brushing of teeth) 
 Help patients with setting alarms on cell 
phones or watches 
 Determine reasonable, specific goals defined 
by the patient 
Reinforce patients in a positive manner
 Teach parents to offer labelled praise for 
adherence behaviour and ignore minor 
misbehaviour 
 Help patients with introducing visible 
reminders at home
 Age-appropriate explanation of the disease 
process and treatment 
 Address real or perceived fears regarding 
side-effects of medication
 Motivational interviewing by healthcare 
provider at follow-up visits 
 Consistent follow-up by the same 
healthcare provider
 Asthma diaries to assess symptoms and 
treatment administration
 Dose counters, canister weights and 
prescription refills
Electronic monitoring devices
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education is followed by a request for the patient to repeat the 
information to the practitioner, fosters better patient understand-
ing (evidence level B). Using open questions and non-judgemental 
questioning may allow a more accurate measurement of adherence 
(evidence level C). For example, before questioning, acknowledging 
that most people have some degree of non-adherence and then asking 
how often the patient forgets to use their medication, may be more 
successful than simply asking how often medication is used. 
The use of a personalised, written asthma action plan does not 
improve lung function, but does result in fewer days lost from 
work and school, fewer emergency department visits and hospital 
admissions, fewer nocturnal symptoms, less use of rescue medication 
and better quality of life (evidence level A). Asthma self-management 
plans may be based on symptoms and/or peak flows (depending on age 
and ability). Self-management plans based on symptoms are as effective 
as those based on peak flow measurement (evidence level A). 
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Appendix A. The SA Childhood Asthma Working Group (SACAWG)
Epidemiology: H Zar (leader), Western Cape; C Gray, Western Cape.
Diagnosis of asthma: R Masekela (leader), KwaZulu-Natal; S M Risenga, Limpopo; O P Kitchin, Gauteng; P Goussard, Western Cape.
Assessment of asthma control: R J Green (leader), Gauteng; A van Niekerk, Gauteng; D White, Gauteng; G Davis, Gauteng.
Pharmacotherapy: F E Kritzinger (leader), Western Cape; A Jeevanathrum, Gauteng; P de Waal, Free State; S Kling, Western Cape; A Vanker, 
Western Cape; T C Gray, Western Cape; J Morrison, Western Cape; A Puterman, Western Cape; E Zöllner, Western Cape; D Rhode, Western Cape.
Pharmacotherapy – other therapies: A I Manjra (leader), KwaZulu-Natal; P M Jeena, KwaZulu-Natal; V Naidoo, KwaZulu-Natal; 
M Annamalai, KwaZulu-Natal; A van Niekerk, Gauteng.
Self-management plans: M Levin (leader), Western Cape; S Emanuel, Western Cape; D Hawarden, Western Cape; H Katz, Gauteng.
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Appendix B. Grades of Recommendation Assessment, Development and Evaluation (GRADE) 
Level of recommendation Quality of evidence Definition
A High High-quality research very unlikely to change our confidence in the estimate effect based 
on level I evidence
B Moderate Moderate-quality evidence, where future research is likely to have an important impact 
on our confidence in the estimate effect. Based on level II evidence or extrapolated from 
recommendations from level I evidence
C Low Low-quality evidence, where future research is likely to have an important impact on our 
confidence in estimate effect. Based on level III evidence or recommendations from 
level I and II evidence
D Very low Very-low-quality evidence, where the estimate effect is uncertain. Based on level IV 
evidence or recommendations from level I, II and III evidence
Appendix B. Level of evidence 
IA   Evidence from meta-analysis and randomised controlled trials
IB   Evidence from at least one randomised controlled trial
IIA Evidence from at least one controlled trial without randomisation
IIB Evidence from at least one or other quasi-experimental study
III  Evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case-controlled studies
IV  Evidence from expert committee reports, opinions or clinical experience of respected authorities
